Harnessing Immune Response in Acute Myeloid Leukemia

Harnessing Immune Response in Acute Myeloid Leukemia

Despite the results achieved with the evolution of conventional chemotherapy and the inclusion of targeted therapies in the treatment of acute myeloid leukemia (AML), survival is still not satisfying, in particular in the setting of relapsed/refractory (R/R) disease or elderly/unfit patients. Among...

Full description

Bibliographic Details
Main Authors: Carola Riva, Chiara Vernarecci, Paola Minetto, Rayan Goda, Marco Greppi, Silvia Pesce, Maria Chies, Giada Zecchetti, Beatrice Ferro, Elena Maio, Michele Cea, Roberto Massimo Lemoli, Emanuela Marcenaro, Fabio Guolo
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Journal of Clinical Medicine
Subjects:
AML
immunotherapy
CAR-T
NK cells
Online Access:https://www.mdpi.com/2077-0383/12/18/5824

Internet

https://www.mdpi.com/2077-0383/12/18/5824

Similar Items